Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 2, 1999, Pages 178-179

  Boiardi, Amerigo ^a   Pozzi, Annalisa ^a   Salmaggi, Andrea ^a   Eoli, Marica ^a   Zucchetti, Massimo ^b   Silvani, Antonio ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; LIPOSOME;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDULLOBLASTOMA; PRIORITY JOURNAL; RECURRENT CANCER;

ANTIBIOTICS, ANTINEOPLASTIC; BRAIN NEOPLASMS; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; LIPOSOMES; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS;

EID: 0032902371     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050881     Document Type: Article

References (9)

1. Albrecht KW, Leenstra S, Bakker PJM, Beijnen JH, Troost D, Kaaik P, Veenhof CHN, Bosch DA (1997) High concentrations of daunorubicin and daunorubicinol in human malignant astrocylomas after systemic administration of liposomal daunorubicin. Proceedings, ASCO meeting, 17-20 May, Denver, Colorado
2. Boiardi A, Salmaggi AL, Pozzi G, Broggi A, Silvani A (1996) Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. J Neurooncol 27: 157-162
3. D'Incalci M, Broxterman HJ, Kalken CK van (1991) Membrane transport in multidrug resistance, development and disease. Ann Oncol 2: 635-639
4. Forssen EA, Ross ME (1994) Daunoxome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4: 481-512
5. Forssen EA, Coulter DM, Proffit RT (1992) Selective in vitro localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52: 3254-3261
6. Kaiijk P, Troost D, De Boer OJ, Van Amstel P, Bakker PJM, Leenstra S, Bosch DA (1996) Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multi cellular spheroids of glioblastomas. Br J Cancer 74: 187-193
7. Perego P, Boiardi A, Carenini N, De Cesare M, Dolfini E, Giardinio R, Agnani I, Silvani A, Soranzo C (1994) Characterisation of an established human malignant glioblastoma cell line and its response to conventional drugs. J Cancer Res Clin Oncol 120: 585-592
8. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatement of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83: 1029-1037
9. Wiles ME, Bell C, Lindfair D, Bendele R (1997) Daunorubicin and doxorubicin: comparable cytotoxicity in vitro for 14 different tumor cell types. Proceedings, ASCO meeting, 17-20 May, Denver, Colorado